$BIAF News

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

bioAffinity Announces Publication Of Clinical Review And White Paper For Incorporating CyPath Lung Into Pulmonary Nodule Evaluation And Cancer Surveillance

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

bioAffinity, Pictor Collaborate To Integrate Flow Cytometry And Proteomic Analysis Platform To Analyze Immune Cell Populations And Cytokine Profiles Related To Airway Inflammation

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

BioAffinity Technologies Announces 200% Sales Growth YoY For CyPath Lung Cancer Diagnostic

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics Symposium

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies Announces Closing of $3.2 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

bioAffinity Technologies Prices $3.2M Offering Of 4M Shares (Or Pre-funded Warrants) At $0.80/Share ($0.793/Warrant)

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung

BioAffinity Technologies Reports April CyPath Lung Diagnostic Unit Sales Up 300% YoY

bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY

bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate